Recent findings suggest that the inhibition of Aurora A (AURKA) kinase may offer a novel treatment strategy against metastatic cancers. In the current study, we determined the effects of AURKA inhibition by the small molecule inhibitor MLN8237 both as a monotherapy and in combination with the microtubuletargeting drug eribulin on different stages of metastasis in triplenegative breast cancer (TNBC) and defined the potential mechanism of its action. MLN8237 as a single agent and in combination with eribulin affected multiple steps in the metastatic process, including migration, attachment, and proliferation in distant organs, resulting in suppression of metastatic colonization and recurrence of cancer. Eribulin application induces accumulation of active AURKA in TNBC cells, providing foundation for the combination therapy. Mechanistically, AURKA inhibition induces cytotoxic autophagy via activation of the LC3B/p62 axis and inhibition of pAKT, leading to eradication of metastases, but has no effect on growth of mammary tumor. Combination of MLN8237 with eribulin leads to a synergistic increase in apoptosis in mammary tumors, as well as cytotoxic autophagy in metastases. These preclinical data provide a new understanding of the mechanisms by which MLN8237 mediates its antimetastatic effects and advocates for its combination with eribulin in future clinical trials for metastatic breast cancer and early-stage solid tumors.
Introduction
Kinases are considered to be the first-line targets for designing anticancer therapies, due to their suitability of inhibition and importance in cell signaling. Of the three members of the Aurora kinase family, Aurora kinase A (AURKA) is well known for its role in mitosis (1) and can be successfully targeted to inhibit proliferation (2) . Elevated AURKA protein levels are a negative prognostic marker of breast cancer patient survival (3) . Breast cancer cells have increased levels of active AURKA, which in turn could lead to an increase in mitotic slippage/escape and accumulation of aneuploid cells, resulting in more aggressive cancer (4) . The potent, highly selective, and orally available AURKA inhibitor MLN8237 (alisertib, IC 50 ¼ 6.7 nmol/L; ref. 5 ) is currently in phase I-III clinical trials to treat solid and hematologic cancers (6) . Treatment with AURKA inhibitors leads to multiple defects, including mitotic deficiency, apoptosis (7) , and senescence, in multiple human tumor cell lines (6, 8) . MLN8237 demonstrated promising antitumor activity toward hematologic, lymphatic, and CNS malignancies (9) (10) (11) (12) (13) . In phase I-II trials for advanced solid tumors, MLN8237 as a single agent was able to stabilize the disease in few cases (14) (15) (16) (17) (https://clinicaltrials.gov/). The antitumor activity of MLN8237 was also tested in combination with standard-of-care agents, including paclitaxel (18) . In some cases, combination therapy provided enhanced antitumor activity in comparison with either agent alone (19) . Many metastatic breast cancers are resistant to taxanes and currently are treated with a nontaxane microtubule inhibitor, eribulin mesylate (20) , which induces mitotic arrest and apoptosis (21, 22) . Eribulin has been approved as a monotherapy for patients with metastatic breast cancer (23) . The therapeutic benefit of eribulin in combination treatment with AURKA inhibitors is currently unknown. The antitumor activity of AURKA inhibition toward breast cancer cells in vitro has been reported (24) (25) (26) (27) . Nevertheless, little is known about the effect of MLN8237 on metastasis as a process and the treatment of established metastases. We have previously reported on the inhibition of pulmonary metastases by AURKA inhibitors (28) . The mechanisms behind this phenomenon are still unknown. In our current work, we analyzed step by step the effects of MLN8237 alone or in combination with eribulin to define the specific stages of metastasis most affected by the drugs. We also document their ability to eradicate distant metastases in mouse models of breast cancer and patient-derived xenografts via simultaneous inhibition of migration and proliferation, along with activation of cytotoxic autophagy. The combination of MLN8237 with eribulin results in increased apoptosis in mammary tumors, leading to the additional benefit of local control and a drastic decrease in the number of bone metastases. Application of MLN8237 plus eribulin in adjuvant and metastatic settings could potentially lead to a significant regression of tumor growth in all sites, which would improve survival. In addition, observed activity in adjuvant settings may lead to a decrease in recurrence risk, thus improving disease-free survival and possibly overall survival in earlier stages.
Materials and Methods

Cell lines and reagents
BT-549 and MDA-MB-231LN cells were obtained in 2011 to 2012 from ATCC and Caliper, amplified on the basis of the manufacturer's recommendations; from multiple frozen aliquots, one aliquot of each was thawed for this project. All cell lines come with comprehensive authentication and quality assurance testing by ATCC/Caliper via short tandem repeat profiling; no authentication was done by the authors. HCI_001 and HCI_002 are triple-negative breast cancer (TNBC) primary cells kindly provided by Dr. Alana Welm (Huntsman Cancer Institute, University of Utah, Salt Lake City, UT) through a shared MTA agreement; PEN65 ER
À primary cells from WVU Center Institute (West Virginia University, Morgantown, WV) were freshly isolated in 2015 from patient-derived xenografts using previously published protocols (29) , frozen, and cultured less than one months; no authentication was done by the authors. All cells were routinely screened for the absence of mycoplasma. siRNAs, cell medium, and supplements were prepared as described previously (28) . Eribulin mesylate (Halaven) was kindly provided by MBR Cancer Center pharmacy. MLN8237 and chloroquine were purchased from SelleckChem and Sigma-Aldrich respectively.
Cell proliferation and nuclear morphology analysis Cell proliferation was determined using the Countess II Automated Cell Counter. Cells (1 Â 10 4 ) were treated with serial dilutions: 0, 25, 50, 100, and 150 nmol/L MLN8237; 0, 1, 3, and 5 nmol/L eribulin; or combination in triplicates for 48 hours (n ¼ 3). Viable cells were counted on the basis of trypan blue exclusion assay. Nuclear morphology was analyzed in 100 cells/treatment, n ¼ 3 using Hoechst 33342, cleaved caspase-3, and Annexin V (BD Biosciences) staining under 100Â objective, Axiovert200/Zeiss microscope. Annexin V and cleaved caspase-3-positive cells with condensed/fragmented DNA were counted as apoptotic. Cells with mitotic figures, large abnormally shaped nuclei, or multiple small nuclei were assigned in separate categories.
Western blotting
Western blotting was performed using standard procedures (28) . Primary antibodies included anti-AURKA (BD Biosciences), -SQSTM1/p62, -LC3B, -Akt, -cleaved PARP, -phospho-T288 AURKA (Cell Signaling Technology), pAkt/S473 (R&D), -bactin, -a-tubulin (Sigma), and GAPDH (Millipore). Secondary antimouse, anti-rabbit HRP-conjugated antibodies (Jackson ImmunoResearch), dilution 1:10,000 followed by chemiluminescencebased detection with HyGLO (Denville Scientific). Bands were quantified using the digital electrophoresis documentation and image analysis software Gene Tools (Syngene Corp.), with signal intensity normalized to b-actin, a-tubulin, or GAPDH.
3D migration/invasion
Studies were carried out in 3D Chemotaxis m-Slides (ibidi) according to the manufacturer's protocol. Briefly, attached cells were pretreated overnight with vehicle, 100 nmol/L MLN8237, 3 nmol/L eribulin, or combination (100 nmol/L MLN8237 þ 3 nmol/L eribulin); deattached, and 3 Â 10 6 cells/mL were suspended in 3 mg/mL Matrigel (BD Biosciences). Vehicle/or drugs were included in medium and Matrigel. Imaging was done using a Nikon-Sweptfield/Eclipse TE2000-E confocal microscope with 10Â Plan Apo DIC objective every 15 minutes for 23 hours. Time-lapse images were combined to build the video files and analyzed using ImageJ software/NIH (Bethesda, MD). The tracks of individual cell movement were manually mapped using MTrackJ plugin to measure cell body and leading edge speed, distance, and directionality (30) . Detailed analysis is provided in Supplementary Methods.
Immunofluorescent cell analysis
The cells were processed as described previously (31) . Primary antibodies included anti-cleaved caspase-3, -LC3B, -SQSTM1/ p62, phospho-mTOR/S2448, phospho-Bad/S112, phosphoErk1/2 Thr202/Tyr204 (Cell Signaling Technology), -pAkt/S473 (R&D Systems), phospho-T288-AURKA (Bethyl Laboratories), -actin, a-tubulin (Santa Cruz Biotechnology), and phospho-histone H3 (BD Biosciences). Secondary antibodies included Alexa Fluor 488, 555, and 647 (Life Technologies). Images were captured using the confocal microscope LSM-510/Zeiss equipped with Photometrics QuantEM CCD camera (Photometrics), 63Â Plan Fluor, NA 1.4 objective. Images were captured every 0.35 mm, followed by 3D reconstruction using LSM/Zeiss and ImageJ/NIH software. The images inside each dataset were collected with the same microscopy and image capture settings, and the raw data were used for image and statistical analysis.
FACS
FACS was performed as described previously (32) . The detailed protocol is provided in Supplementary Methods.
Fluorescent IHC
The detailed fluorescent IHC (F-IHC) protocol and used antibodies are provided in Supplementary Methods. IHC images were obtained using LSM-510/Zeiss fluorescent microscope of 20Â objective. Images were analyzed and intensity was calculated via ImageJ software (NIH). For quantifications, the signal from corresponding antibodies was normalized by area and number of nuclei. Metastases borders were determined by an overlay with hematoxylin and eosin (H&E), nuclear morphology, cytokeratin staining, and interpreted by a pathologist.
Anoikis assay
Attached cells were pretreated with vehicle, 3 nmol/L eribulin, 100 nmol/L MLN8237, or combination for 24 hours, then trypsinized and placed on Ultra-Low Attachment Plates (Corning) with complete medium containing drugs as indicated above for 48 hours. Drugs were reapplied every 24 hours. Anoikis-induced apoptosis was detected via staining with Annexin V-FITC (BD Biosciences), propidium iodide (PI; Sigma) containing 10 mg/mL RNase, or anti-cleaved caspase-3 antibody (BD Biosciences) via FACS.
Cell adhesion and spreading assay
Cells were pretreated with drugs as above, trypsinized, and 1 Â 10 4 cells per well were plated in vehicle/or drugs-containing medium. Multiple bright-field images were taken at 10Â magnification every 20 minutes for 1 to 2 hours. The area of individual attached cells was quantified using ImageJ software, 100 cells analyzed per time point.
Xenograft models of breast cancer and treatments
Orthotopic and tail vein injections were performed as previously described (28) approved Institutional Animal Care and Use Committee (IACUC) protocol. Treatment with vehicle, 20 mg/kg MLN8237, 0.6 mg/kg eribulin, or combinations (10 mg/kg MLN8237, 0.3 mg/kg eribulin) was initiated when primary tumors reached 500 mm 3 , as measured by ultrasound Vevo2100 system (VisualSonics). In tail vein models, mice were treated with similar regiments, including 20 mg/kg chloroquine and 20 mg/kg MLN8237 þ 20 mg/kg chloroquine. MLN8237 was administered via oral gavage twice daily for 4 days per week for 2 to 3 weeks (28) . Eribulin was administrated every other day by intraperitoneal injection for 2 to 3 weeks. Chloroquine was administrated for 5 days per week by intraperitoneal injection once daily for 2 weeks. At the end of the study, the primary tumors, lungs, and bones were collected and fixed. Consecutive 4 to 5 mm sections were used for F-IHC and H&E staining, followed by mitotic index quantification.
Survival studies
In female mice, 500 mm 3 mammary tumors were resected and mice treated with vehicle or MLN8237 (20 mg/kg) for 2 weeks. Male NSG mice were injected via tail vein with 1 Â 10 5 MDA-MB-231LN cells and treated one week after injection with a similar regiment. The last day of the treatment was assigned as the starting point of survival study: "day 0." The mice were monitored daily for signs of weight loss and distress. Mice were euthanized when they reached critical health condition according to WVU/IACUC tumor guidelines.
Patient-derived xenograft models
Breast cancer biopsies were collected through the WVU Cancer Institute (Morgantown, WV) or Cooperative Human Tissue Network (NCI) in accordance with WVU and CHTN-approved IRB protocol. A total of 2 Â 2 mm 3 of tumor tissue was implanted into the precleared fourth inguinal mammary gland of NSG female mice for 2 to 6 months. Tumors [500 mm 3 ; patient-derived xenografts (PDX); Supplementary Table S1 ] were resected, and mice were treated as described above. Multiple internal organs were collected, fixed, and embedded in paraffin after treatment for pathologic evaluation. Disseminated tumor cells in femurs were quantified from fresh bone marrow samples, which were minced, plated in medium, and allowed to attach for 24 hours. For fixed samples, serial sections with 5-mm intervals were made from each organ, stained with H&E, and analyzed for metastases.
Time course study of metastatic colonization
Male NSG mice were injected with 1 Â 10 5 MDA-MB-231LN cells via tail vein injection. Immediately following injection of cancer cells, mice were treated with MLN8237 or vehicle as above. Mice were euthanized at 24, 48, and 72 hours after cell injection/initial treatment. Upon euthanasia, lungs were collected, fixed, and embedded in paraffin. Serial sections (5 mm) through the whole lungs were made, stained with H&E, and analyzed for metastases (single cell, clustered cells) by pathologist.
Laser ablation electrospray ionization mass spectrometry analysis
Detailed protocol/analysis is provided in Supplementary Methods.
Statistical analysis
Statistical comparisons were made using two-tailed Student t test. When more than two groups were analyzed, one-way or twoway ANOVA was used. P 0.05 was considered to be significant ( Ã ) as indicated in the figure legends. All treatment groups were compared with vehicle unless mentioned otherwise. Experimental values were reported as the means with AESEM, and calculations of statistical significance were made using GraphPad software. Additional statistical methods, including synergy analysis, are provided in Supplementary Methods.
Results
Application of eribulin leads to an increase in active AURKA In our study, we found that the application of FDA-approved breast cancer antimetastatic agent, eribulin, as a single agent results in a significant increase in the active form of AURKA in TNBC cells and xenografts ( Fig. 1A and B and Supplementary Fig.  S1A and S1B). The combination of eribulin with MLN8237 eliminates this effect and decreases the amount of active AURKA. To test whether AURKA expression could be a potential biomarker of the patient's response to eribulin, we depleted AURKA via application of anti-AURKA siRNAs and assessed the viability of cells. The decrease in AURKA expression resulted in little to no effect on viability of MDA-MB-231 cells, which have mutant p53 and significant upregulation of endogenous AURKA. Depletion of AURKA in the patient-derived TNBC cell line HCI_002 potentiated eribulin treatment and resulted in an increase in cell death (Supplementary Fig. S1C and S1D), suggesting that combination of these drugs might significantly improve the treatment outcomes of metastatic breast cancer patients. Next, we tested the effects of MLN8237 and combination on different stages of metastatic cascade.
MLN8237 and eribulin reduce 3D motility/invasion and adhesion of breast cancer cells
We have previously reported that the activity of AURKA is critical for stabilization of actin at the leading edge of migrating tumor cells (31) . Cells treated with eribulin also show decreased motility (22) . In the current work, we have tested the impact of AURKA inhibition as a single agent or in combination with eribulin on 3D migration/invasion using time-lapse microscopy. The treatment of TNBC cells embedded in basal membrane-like matrix (Matrigel) with MLN8237 reduces the speed, distance, and directionality of cell movement ( Adhesion is an important step in cancer cells intra/extravasation to colonize distant organs. We tested whether MLN8237 alone or in combination with eribulin impairs the ability of breast cancer cells to attach to a physiologically relevant matrix. There was a significant decrease in the ability of cancer cells to attach/ spread upon treatment with MLN8237 ( Fig. 1F and G), suggesting that AURKA activity is required for formation/stabilization of cell/ matrix adhesions, but the combination with eribulin did not result in an additional benefit.
MLN8237, eribulin, or combination does not affect sensitivity of breast cancer cells to anoikis
Circulating tumor cells released by solid tumors must develop a resistance to anoikis and survive in the blood/lymphatic system to reach distant organs. To test whether inhibition of AURKA or application of eribulin may sensitize breast cancer cells to anoikis, attached cells were pretreated with drugs or vehicle for 24 hours, deattached, and replated on low attachment plates for 48 hours in the presence of drugs or vehicle. FACS and microscopy-based observation of nuclear morphology documented no difference in sensitivity to anoikis between the treatment groups based on Annexin V, cleaved caspase-3, or PI staining ( Fig. 2A-C) , suggesting that neither MLN8237 nor eribulin have any effect on anoikis sensitivity in TNBC cells.
Combination of eribulin and MLN8237 leads to synergistic induction of cell death in attached breast cancer cells
Treatment of breast cancer cells attached to the matrix with MLN8237 or eribulin has little to moderate effect on the induction of cell death, with 5% to 10% of cells found to be Annexin V, cleaved PARP, or PI positive 48 hours posttreatment. Importantly, combination of these drugs led to a synergistic increase in the number of dead cells ( Fig. 2D and E, FACS charts, Supplementary Fig. S2 ). Attached breast cancer cells were further tested for sensitivity to combination therapy via serial dilutions of both drugs (Fig. 2F) . The number of live/dead cells after 48 hours of treatment in each dilution was used for assessment of drug interaction in vitro using three different statistical methods as described in the Supplementary Methods. The statistical analysis confirmed a synergistic mode of interaction between these drugs (Table 1) . MLN8237 alone or in combination reduces metastases in vivo through the inhibition of proliferation/prosurvival pathways and promotion of cytotoxic autophagy
FACS
To determine the impact of MLN8237 and eribulin therapy on mammary tumors and established metastases, we utilized breast cancer orthotopic xenograft models. MDA-MB-231LN cells were injected in the mammary fat pad of NSG mice to form mammary tumors (500 mm 3 ) and then treated with drugs as indicated. In agreement with our previous findings, MLN8237 did not suppress the growth of mammary tumors; however, it drastically reduced the number of pulmonary metastases (Fig. 3A, B , and E; refs. 28, 31) . The combination therapy led to significant reduction in the size of mammary tumor and metastases (Fig. 3B) . Interestingly, eribulin alone has no effect on the number of metastases but reduces their size when compared with vehicle (Fig. 3A) , suggesting cytostatic rather than cytotoxic activity in lungs.
To define the potential mechanisms, we analyzed lung metastases and mammary tumors for expression of markers for proliferation (Ki67, pERK1/2), survival (pAKT/S473, p-mTOR/S2448), apoptosis (cleaved caspase-3, pBAD/S112), and autophagy (LC3B, p62/SQSTM1) via quantitative F-IHC staining and Western blot analysis. MLN8237, eribulin, and combination treatments decrease the proliferation and survival of tumor cells at the metastatic site (lungs) by 80% to 90%, as indicated by decreases in Ki67 expression and phosphorylation of AKT ( Fig. 3C and E) and its downstream substrates mTOR (33) and BAD (34) (Supplementary Fig. S3A and S3B ). The activity of caspase-3, a prominent marker of apoptosis, was not affected in metastases, while slight decrease in phosphorylation of BAD, a proapoptotic member of the Bcl-2 family, indicates autophagy-promoting effect of BAD, potentially via release of Beclin1 from Bcl2 complex (35) . Expression of p62/SQSTM1 and LC3B significantly increased in MLN8237 and combination-treated metastases, but not in metastases treated with eribulin alone, suggesting the involvement of autophagy in the clearance of metastases (Fig. 4A and C) .
The effect of MLN8237 on proliferation/Ki67 of mammary tumor cells was lower, but statistically significant, with minimal changes in pAKT and p-mTOR (Fig. 3D and F and Supplementary  Fig. S3C, S3D , and S3F). The increase in pERK1/2 and pBAD, which might be indicative of active cell-cycle and inhibition of apoptosis (36) , was significant in MLN8237-treated tumors (Supplementary Fig. S3C and S3D ). MLN8237 treatment did not induce upregulation of p62/LC3B or activation of caspase-3 in mammary tumors in agreement with the limited effect on tumor size.
Eribulin and combination therapy, however, significantly reduced the size of mammary tumors, which correlates with the decrease in Ki67, p-mTOR, pERK1/2, pBAD and increase in p62, LC3B, and cleaved caspase-3 expression (Fig. 4B and D and Supplementary Fig. S3C and S3D ), which suggests involvement of both pathways (autophagy and apoptosis) in the reduction of mammary tumors. pAKT was slightly upregulated in eribulin and combination-treated mammary tumors, which correlates with the redistribution of AKT from the nucleus (observed in vehicle and MLN8237) to the cytoplasm, which was previously shown to correlate with induction of apoptosis (37) . The DNA panels for the immunohistochemical staining are included in Supplementary Fig. S4 . In addition to H&E staining and nuclear morphology, metastases were confirmed via cytokeratin staining (Supplementary Fig. S5 ).
Next, we analyzed the lysates prepared from mammary tumors and lung metastases using Western blotting to assess the levels of the indicated above markers. MLN8237 increased LC3B staining and conversion to the LC3B-II form in lysates of lung metastases, but not in mammary tumors ( Supplementary Fig. S6A-S6C) . Because of the small size of the eribulin and combination-treated mammary tumors and lung metastases, the levels of cleaved caspase-3, p62, and pAKT were not detectable.
As a complementary approach, we amplified and treated in vitro the tumor cells isolated from mammary tumors and lungs of vehicle-treated mice. Expression of most markers was similar to the levels observed in tumors and metastases by IHC, but the levels of p62 and pAKT did vary and were, on average, higher in mammary tumor cells than lung metastases (Fig. 4E) . Cleaved PARP, a downstream target of active caspase-3, was elevated in eribulin and combination-treated cells, suggesting an activation of apoptosis, which is in agreement with the IHC data. Addition of chloroquine, an inhibitor of autophagy, resulted in further increases in p62 and LC3B in cells isolated from both sites, suggesting that in vitro, both types of cells had significant levels of basal autophagy potentially due to in vitro culturing conditions ( Fig. 4E and F) .
Similar to F-IHC data, immunofluorescent staining of p62 in MLN8237-treated cells isolated from lung metastases shows upregulation of p62 and decrease in pAKT. Addition of chloroquine leads to further increase in p62 levels, indicating the presence of active autophagic flux ( Supplementary Fig. S7A and S7B). Immunofluorescent staining of p62 in cells isolated from MLN8237-treated mammary tumors shows active autophagic flux only in eribulin and combination-treated cells (Supplementary Fig. S7C and S7D) . Analysis of nuclear morphology in these cells shows a significant increase in apoptotic and polynucleated cells upon treatment with eribulin or combination, whereas MLN8237 causes an increase in abnormally shaped nuclei, potentially due to an increase in aneuploidy (Supplementary Fig. S7E and S7F) . 
MLN8237 reduces colonization potential of metastatic cells
As only MLN8237 or combination therapy was able to decrease the number and size of pulmonary metastases, the effect of MLN8237 as a single agent on seeding and colonization of new metastases by circulating tumor cells was tested. MDA-MB-231LN cells were injected intravenously into NSG male mice via tail vein and immediately treated with vehicle or MLN8237 (Fig. 5A) . The total flux and average radiance of injected animals was measured but did not significantly differ during the experimental time frame. Mice were euthanized and lungs were harvested at 24, 48, and 72 hours post injection/treatment. Note that based on our previously published work and in vitro results, treatment with (28) . In agreement with these findings, a similar number of singlecell metastases was found in the lungs of mice at 24 hours postinjection. By 48 hours, in both MLN8237 and vehicle-treated groups, some of the single-cell foci underwent one to two rounds of division forming "mixed metastases," represented by a combination of single-cell and 2 to 4 cell clusters (Fig. 5B and C) . However, by 72 hours of treatment, MLN8237 was able to reduce both the size and also total number of metastases (independent of size) in lungs (Fig. 5D ). Under these conditions, the potential difference in the number of cells in circulation released by primary tumors was eliminated, suggesting that MLN8237 specifically inhibits the colonization and growth of metastases.
MLN8237 treatment improves overall survival via eradication of metastases by cytotoxic autophagy
To assess the impact of MLN8237 on overall survival, we injected breast cancer cells into the mammary fat pad, followed by mammary tumor growth (500 mm 3 ) and surgical resection. Mice were then treated with MLN8237 or vehicle in adjuvant settings for 2 weeks (Fig. 5E ). After treatment, mice were monitored daily and then euthanized once a critical health condition was reached based on a veterinarian evaluation. Importantly, MLN8237 treatment in an adjuvant setting was able to increase the lifespan of mice by 31%, increasing from an average survival age of 19 days posttreatment in the control group to 32 days in the MLN8237-treated group. Twelve percent of MLN8237-treated mice remained tumor free until they were euthanized at 2 years old after the end of the study (Fig. 5F ), indicating that MLN8237 significantly prolongs survival when used as a postoperative standard-of-care treatment. Interestingly, only half of the MLNtreated animals had a recurrent mammary gland tumor when compared with the control group (Fig. 5G) . To assess the impact of MLN8237 on the survival of animals with metastases in a genderunbiased assay and independent from possible mammary tumor size differences or surgery quality, breast cancer cells were introduced via tail vein injection into male mice (Fig. 5H) . Treatment with MLN8237 prolonged the survival of males twice more efficiently (by 62%) in the tail vein model, going from a median survival of 28 days in the control group to 46 days in the MLN8237-treated group (Fig. 5I and J) . Similar to our earlier findings, the decrease in proliferation and survival markers was observed in lung metastases upon MLN8237 treatment (Supplementary Fig. S8A and S8B ). To determine that decrease in metastases is driven by cytotoxic autophagy, we have performed similar metastatic colonization/growth study with addition of chloroquine, inhibitor of autophagy. Chloroquine alone did not affect metastatic growth when compared with vehicle, but its addition to MLN8237 completely blocked MLN's potential to suppress metastatic outgrowth, confirming pivotal role of autophagy in eradication of metastases in vivo (Fig. 5K-M) .
MLN8237 is efficient against pulmonary metastases in PDX models
To further evaluate our findings in clinically relevant models, we utilized metastatic breast cancer PDXs. PDX models are significantly better at predicting drug responses in clinic and can replicate the heterogeneity of an original tumor (38) . Five metastatic PDXs (Supplementary Table S1 ) were used in this study: HCI_001, HCI_002, PEN27, PEN25, and PEN65. Passage one PDXs (first transplantation after successful graft of patient's tumor biopsy, Fig. 5N and O) were used for drug evaluation. The grafted tumors (500 mm 3 ) were surgically removed, and mice were treated with MLN8237 or vehicle for 2 weeks; internal organs and mammary tumors (if regrown) were collected for pathologic evaluation. PDX-produced metastases were found in the lungs, lymph nodes, bones, and brain. Number of metastases was significantly lower in the MLN8237-treated group (Fig. 5O) . Recurrence rates of PDX mammary tumors were also significantly decreased upon treatment with MLN8237, suggesting that AURKA targeting may be critical for eradication of the cancer stem-like cells that are responsible for cancer relapse.
MLN8237 plus eribulin is an efficient strategy to control local and distant tumor growth
To gain local control and reduce the number of tumor cells disseminating from the primary site, the combination of MLN8237 with eribulin was tested. First, we tested the effect of combination therapy on growth/viability of primary tumor cells isolated from PDXs (HCI_002 and PEN65). Combination therapy led to significant decrease in proliferation and viability of cells ( Fig. 6A and B and Supplementary Fig. S9A and S9B) when compared with either drug alone. In the case of PEN65, a synergistic decrease in proliferation and increase in apoptosis was observed in combination (Table 2 ). Nucleus morphology analysis of the of HCI_002 and PEN65 cells treated with combination of eribulin and MLN8237 showed an increase in the number of cells with condensed/fragmented (apoptotic) DNA and polynucleated or abnormally shaped nuclei and a decrease in a number of mitotic cells (Fig. 6B and Supplementary Fig. S9B ). Similar to MDA-MB-231LN, the patient-derived cells demonstrated an increase in cleaved caspase-3 staining (Fig. 6C and D) . Cells treated with combination therapy also had increased levels of p62 (Fig. 6E) . To assess the impact of combination therapy on PDX mammary tumor growth in vivo, HCI_002 tumor fragments were transplanted into mammary fat pads of na€ ve NSG mice, and established tumors (500 mm 3 ) were treated with vehicle/or drugs for 3 weeks. The combination therapy led to a 70% to 80% reduction in the volume of PDX mammary tumors versus 40% with eribulin alone (Fig. 6F, week 2) . Statistical analysis using a mixed model shows the significant benefit of combination even with twice less dosage of each drug, suggesting a superior performance with an increase in dosage (Fig. 6G) . The mitotic index in mammary tumors was decreased in animals treated with eribulin and combination, but not with MLN8237 alone, whereas in lung metastases, only MLN8237 and combination treatment had a significant decrease in mitotic index (Fig. 6H) . In addition, the number of disseminated tumor cells to the bone was significantly decreased in eribulin and combination-treated animals, potentially due to the overall decrease in tumor volume or specific action of eribulin on dormant cancer cells in this microenvironment (Fig. 6I) . Notably, eribulin had no effect on the number of disseminated tumor cells to the lungs (Fig. 6J) .
To test whether the limited MLN8237 efficacy in the mammary tumor is a result of poor penetration of the drug, we performed a drug distribution analysis in PDX tumors resected from mice treated with MLN8237 for 2 days using LAESI mass spectrometry imaging (Protea Biosciences). We demonstrate that based on histologic morphology, MLN8237 is present in and around the blood vessels of the tumor ( Supplementary Fig. S10A-S10C) . Localization was further confirmed by a correlative high content of heme groups ( Supplementary Fig. S10D-S10F ). 
Discussion
This study identifies the specific stages of the metastatic process that are most efficiently inhibited by the investigational compound MLN8237 (alisertib), both as a single agent and in combination with the FDA-approved drug eribulin mesylate (Halaven) to benefit metastatic breast cancer patient care. The application of eribulin leads to significant accumulation of cells, with active AURKA justifying the introduction of combination therapy to clinic. AURKA is known to be a promigratory and proinvasive kinase (26, 31) . Our findings indicate that MLN8237 alone or in combination with eribulin reduces the adhesion, speed, and directionality of individual cell invasion but did not affect the sensitivity of TNBC cells to anoikis using in vitro and in vivo models. Promising results of the antiproliferative effect of MLN8237 were previously shown in breast cancer orthotopic models (39) if applied at early stages. Our previous studies in TNBC cell lines MDA-MB-231 and BT-549, however, showed resistance of established mammary tumors to MLN8237 treatment (28, 31) . The effects of MLN8237 þ eribulin combination on cancer cells in the metastatic niche are currently unknown.
Our study shows that MLN8237 alone or in combination with eribulin reduces proliferation of breast cancer cells in lung metastases, suggesting a specific effect of MLN8237 on metastatic cells. Eribulin and combination therapy both reduced proliferation of the primary tumor. MLN8237 treatment also decreased the survival of cancer cells in vitro and in vivo (39) via a reduction in phosphorylation of AKT in metastases, but not primary tumors. Phosphorylated AKT was mainly found in the nucleus of tumors treated with vehicle and MLN8237 and was found to be cytoplasmic in eribulin and combination-treated tumors, suggesting the activation of apoptosis in the latter cases. The treatment of tumor cells in culture did not result in significant changes in AKT or its translocation to the nucleus, suggesting that in vitro conditions have some limitations to reproduce the in vivo phenotype.
The impact of AURKA inhibition on apoptosis is controversial so far, with some reports suggesting that AURKA inhibition induces apoptosis (9, 40, 41) and other reports considering the impact of AURKA inhibition on apoptosis to be insignificant (27) . The effect of MLN8237 on breast cancer cell apoptosis in metastases was not documented. In our study, inhibition of AURKA did not induce caspase-3-dependent apoptosis in pulmonary metastases or the mammary tumor. It is possible that there is an apoptotic effect of MLN8237, which is not caspase-3 dependent. However, our results indicate that MLN8237 treatment induces cytotoxic autophagy specifically in pulmonary metastases, which may significantly contribute to the antimetastatic effect of MLN8237. It has been shown that autophagy can cause cancer cell death in a caspase-3-independent manner (42, 43) . An increase in autophagy can also facilitate cancer survival (cytoprotective autophagy) and has been documented in some tumors treated with anticancer drugs (44) . Although it still might be the case in the primary mammary tumor, MLN8237 clearly induces cytotoxic autophagy in metastases, as indicated by a decrease in pAKT and an increase in p62 and processed form of LC3B. Eribulin alone or in combination induces apoptosis in TNBC cells based on the presence of cleaved PARP and caspase-3 but simultaneously increases the level of autophagy markers p62 and LC3B. It was previously shown that apoptosis can suppress autophagy, and thus, accumulation of p62 and LC3B may reflect the inhibition of autophagic flux. To test for this possibility, we cotreated cells with autophagy inhibitor chloroquine along with MLN8237 or eribulin. Chloroquine treatment led to further increase in p62 and LC3B, which argues against the inhibition of autophagic flux and supports the idea of potential cooperation between both types of cell death in combination therapy. The combination therapy provided synergistic activation of apoptosis, leading to an increase in cell death, drastically reducing tumor mass at the primary site and metastases in multiple sites, including bone lesions, which are the most common and difficult to treat. Even at the half dosages used in combination, the effect was superior to either drug with twice higher concentration, suggesting that usage of this regiment may significantly reduce side effects of therapy in the clinic.
The mass spectrometry analysis of flash-frozen mammary tumors isolated from MLN8237-treated animals is indicative of blood-based MLN8237 delivery/distribution in the tumor tissue. Thus, tumors with limited blood vessel density may experience limited effects of MLN8237 when compared with lung lesions. In MLN8237 þ eribulin combination reduces primary tumor, metastases, and dissemination of cancer in PDX models. A, HCI_002 cell growth analysis, 48 hours; vehicle, 100 nmol/L MLN8237, 3 nmol/L eribulin, or combination; n ¼ 3, one-way ANOVA: vehicle versus treatments. B, analysis of the nuclear morphology, cells as in A; one-way ANOVA: vehicle versus treatments in each category: mitotic, abnormal nucleus, polynucleated (Polynucl.), apoptotic, normal. C, representative immunofluorescent images of HCI_002 cells treated as in A with anti-cleaved caspase-3 antibodies, DNA. Scale bar, 20 mm; white arrow, apoptotic DNA. D, quantification of cleaved caspase-3-positive cells using immunofluorescent images as in C; one-way ANOVA: vehicle versus treatments. E, immunofluorescent-based analysis of cells as in A with p62 antibodies; the relative intensity (RUI) of the immunofluorescent signal from 3 independent experiments; 100 cells/treatment, one-way ANOVA: vehicle versus treatments. F, tumor volume analysis of HCI_002-PDX mammary xenografts in three cohorts, n ¼ 6 per cohort. Tumor growth was normalized to time point zero of treatment (100%) in each cohort; one-way ANOVA: vehicle versus treatments. G, statistical analysis of the data as in F using mixed model. H, mitotic index analysis of metastases/lungs or mammary tumors as in F, n ¼ 50 cells per treatment in 3 experiments, t test. I, analysis of disseminated tumor cells in femurs of mice as in F; n ¼ 2 per mouse; one-way ANOVA: vehicle versus treatments. J, quantification of lung metastases; serial sections of lungs from three mice per treatment, one-way ANOVA: vehicle versus treatments. MLN8237 and combination-treated mice did not have metastases; arrows and zero signs visualize the absence of signal. agreement with our findings, limited preclinical and clinical efficacy of MLN8237 was documented in the treatment of solid tumors, where MLN8237 could stabilize the disease but was incapable of reducing the tumor size (15); meanwhile, blood malignancies in xenograft mouse models show an extreme sensitivity to the MLN8237 compound (11) . In both a xenograft model, which incorporates the influence of primary tumor invasion and extravasation, and tail vein injection model, which takes into account only the metastatic colonization stage of disease, we showed that the treatment with MLN8237 significantly increases survival rates. It is expected that combination treatment will improve survival to an even greater degree than MLN8237 alone. Previously, MLN8237 was shown to increase survival in neuroblastoma (45) and acute myelogenous leukemia models (9) . Here, we present the first evidence of such an effect on metastatic breast cancer using PDXs. The recent findings presented at the 2014 San Antonio Breast Cancer Symposium show that breast cancer PDX models most accurately predicted the patient clinical response. Importantly, when combined with eribulin, MLN8237 demonstrates synergistic inhibition of primary tumor and metastases growth, including seeding of the metastases. Our findings indicate that MLN8237 plus eribulin can be used in adjuvant and metastatic settings to improve disease-free survival for breast cancer patients.
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